On this page

Where MVD fits

Microvascular decompression (MVD) aims to relieve a relevant vessel–nerve compression in selected people with TN. EAN describes it as first-line surgery for classical TN when surgery is being considered, generally after insufficient medical control or poor tolerability. That recommendation does not make it initial treatment for all facial pain or require every possible medicine to be tried first.1

Assessment connects the clinical diagnosis and pain phenotype with specialist imaging interpretation, previous treatments, general health and the person's preferences. An MRI label of vascular contact alone cannot determine suitability. Secondary or MS-associated TN needs its own discussion; it is not automatically included or excluded by a single category label.1

What the procedure means

MVD is cranial surgery under general anaesthesia. Access is commonly described as retrosigmoid, behind the ear toward the nerve near the brainstem. The surgeon identifies the relevant vessel relationship and separates vessel and nerve.2

Interposition places material between vessel and nerve; transposition moves and secures the vessel away. Worm's TN cohort describes these approaches within its own practice. A technique name alone does not demonstrate superiority for every anatomy. Clarify whether any additional nerve procedure is proposed, because a combined procedure has a different risk and evidence question.3

Read outcomes precisely

Holste's review reports about 76% BNI I pain freedom without medication among 3,897 adults in 46 studies, at mean last follow-up 1.7 ± 1.3 years. Most studies were retrospective; TN classifications and surgical histories varied, and the overall result does not isolate first MVD. It measures final pain status, not lifelong cure or a time-to-recurrence rate.4

The five-year Danish cohort provides a separate observational perspective on classical/idiopathic TN; it excluded previous TN surgery from the MVD group. Nonrandom allocation, attrition and item-count inconsistencies limit comparison with medical care. Its headline percentage isn't a forecast for an individual or for a repeat operation.3

Benefits and harms need separate definitions

Potential MVD complications include hearing or facial-sensory change, cerebrospinal-fluid leak and other neurological problems, alongside bleeding, infection, stroke, seizures and anaesthetic risks. Some complications can be serious. The risk for an individual depends on the operation proposed and the team's experience.2

Ask whether a reported hearing change was measured or self-reported, and temporary or persistent. Ask how pain freedom and ongoing medicine use are counted. Neither a complication example nor a mixed-indication result should silently become a TN risk estimate. HFS studies measure spasm outcomes and cannot provide TN cure rates.

Fair alternatives and the next conversation

Continued or adjusted medical care, percutaneous techniques and stereotactic radiosurgery remain relevant options. They differ in invasiveness, sensory effects, onset and durability of benefit. A person may be unable or unwilling to undergo cranial surgery; that preference belongs in the decision.5

A 2026 network meta-analysis describes low to very low certainty and predominantly observational comparisons. Its rankings do not establish a universal best procedure.6

Bring questions about the diagnosis, why MVD is proposed, the precise operation, alternatives and follow-up. Healing, medication management and returning pain need an individualized plan with the treating team.

References

  1. Bendtsen L et al. European Academy of Neurology guideline. Eur J Neurol. 2019;26:831–849. Source ↩
  2. Mayfield Brain & Spine. Microvascular decompression (patient information). Source ↩
  3. Worm J et al. Five-year prospective outcomes of medical management and microvascular decompression in trigeminal neuralgia. J Neurol. 2025. Source ↩
  4. Holste K, Chan AY, Rolston JD, Englot DJ. Pain outcomes following MVD for drug-resistant TN: systematic review and meta-analysis. Neurosurgery. 2020;86:182–190. Source ↩
  5. NHS. Trigeminal neuralgia: treatment. Source ↩
  6. Fonseca PEO et al. From MVD to radiosurgery: network meta-analysis. Neurosurg Rev. 2026;49:261. PMID 41793527. PubMed ↩